Free Trial
→ Here’s how you could profit from Elon’s NVIDIA partnership (From Behind the Markets) (Ad)

CureVac Q2 2024 Earnings Report

CureVac logo
$3.30 +0.02 (+0.61%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

CureVac EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

CureVac Revenue Results

Actual Revenue
$15.55 million
Expected Revenue
$10.07 million
Beat/Miss
Beat by +$5.48 million
YoY Revenue Growth
N/A

CureVac Announcement Details

Quarter
Q2 2024
Date
8/15/2024
Time
N/A

Conference Call Resources

CureVac Earnings Headlines

Is CureVac N.V. (CVAC) the Best Get Rich Fast Stock to Buy Now?
February 20 at 10:43 AM | msn.com
EQS-News: CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators
February 19 at 9:52 AM | markets.businessinsider.com
Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
February 22, 2025 | Investors Alley (Ad)
CureVac Earns Repeat Recognition by LexisNexis as One of the World's Top Innovators
February 18, 2025 | finanznachrichten.de
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
February 18, 2025 | finance.yahoo.com
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year in vaccine race
February 17, 2025 | msn.com
See More CureVac Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email.

About CureVac

CureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

View CureVac Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles